356: Phase-II Study of Infliximab for the Prophylaxis of Acute Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)

Hamadani, M.Phillips, G.Elder, P.Jansak, B.Blum, W.Penza, S.Lin, T.S.Farag, S.S.Devine, S.M.2021-01-202021-01-202008-02-01Hamadani, M., Phillips, G., Elder, P., Jansak, B., Blum, W., Penza, S., ... & Devine, S. M. (2008). 356: Phase-II Study of Infliximab for the Prophylaxis of Acute Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). Biology of Blood and Marrow Transplantation, 14(2), 130-131.https://hdl.handle.net/1805/24894en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalInfliximabAcute Graft-Versus-Host DiseaseProphylaxis356: Phase-II Study of Infliximab for the Prophylaxis of Acute Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)Article